Evodiamine exerts inhibitory roles in non‑small cell lung cancer cell A549 and its sub‑population of stem‑like cells

Lu,Xiumin; Zhang,Wenjing; Liu,Yu; Liu,Meimei

doi:10.3892/etm.2022.11682

Evodiamine exerts inhibitory roles in non‑small cell lung cancer cell A549 and its sub‑population of stem‑like cells

Authors:
- Xiumin Lu
- Wenjing Zhang
- Yu Liu
- Meimei Liu
View Affiliations

Affiliations: Department of Laboratory Diagnosis, The Sixth Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150000, P.R. China, Department of Laboratory Diagnosis, The Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150000, P.R. China, Department of Prenatal Diagnosis, The Sixth Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150000, P.R. China
Published online on: November 7, 2022 https://doi.org/10.3892/etm.2022.11682
Article Number: 746
Copyright: © Lu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Evodiamine (EVO) is one of the main components extracted from Evodia rutaecarpa and has been reported to inhibit tumor growth by inhibiting proliferation and inducing apoptosis. Although the anticancer activity of evodiamine has been confirmed, the exact mechanism remains to be elucidated. In the present study, cancer stem‑like cells (CSCs) were successfully enriched from A549 cells by being cultured in serum‑free medium and characterized by detecting stemness markers. Expectedly, the addition of EVO inhibited proliferation, migration and invasion in A549 cells, demonstrating its inhibitory effects on the malignant behaviors of A549 cells. In CSCs derived from A549 cells, EVO treatment promoted cell proliferation while inhibiting migration and invasion. By detecting the hallmarks of the epithelial‑mesenchymal transition (EMT), including E‑cadherin, Vimentin, Slug and Snail via western blotting, it was revealed that EVO treatment inactivated the EMT process and potentially led to the loss of self‑renewal capacity of CSCs and promoted proliferation. By activating the EMT using TGF‑β pretreatment, EVO treatment downregulated the hallmarks of the EMT and led to inactivation of the EMT, indicating its potential mechanism of regulating CSCs via the EMT pathway. The findings suggested that modulation of the self‑renewal capacity of CSCs may affect malignant cancer behaviors following surgery. EVO exerts inhibitory effects not only on cancer cells but also on CSCs in non‑small‑cell lung cancer, and therefore could be used as a promising drug targeting CSCs.

View Figures

View References

1	Yu H, Jin H, Gong W, Wang Z and Liang H: Pharmacological actions of multi-target-directed evodiamine. Molecules. 18:1826–1843. 2013.PubMed/NCBI View Article : Google Scholar
2	Huang DM, Guh JH, Huang YT, Chueh SC, Chiang PC and Teng CM: Induction of mitotic arrest and apoptosis in human prostate cancer pc-3 cells by evodiamine. J Urol. 173:256–261. 2005.PubMed/NCBI View Article : Google Scholar
3	Zhao LC, Li J, Liao K, Luo N, Shi QQ, Feng ZQ and Chen DL: Evodiamine induces apoptosis and inhibits migration of HCT-116 human colorectal cancer cells. Int J Mol Sci. 16:27411–27421. 2015.PubMed/NCBI View Article : Google Scholar
4	Kan SF, Huang WJ, Lin LC and Wang PS: Inhibitory effects of evodiamine on the growth of human prostate cancer cell line LNCaP. Int J Cancer. 110:641–651. 2004.PubMed/NCBI View Article : Google Scholar
5	Wang KL, Hsia SM, Yeh JY, Cheng SC, Wang PS and Wang SW: Anti-proliferative effects of evodiamine on human breast cancer cells. PLoS One. 8(e67297)2013.PubMed/NCBI View Article : Google Scholar
6	Ogasawara M, Matsubara T and Suzuki H: Inhibitory effects of evodiamine on in vitro invasion and experimental lung metastasis of murine colon cancer cells. Biol Pharm Bull. 24:917–920. 2001.PubMed/NCBI View Article : Google Scholar
7	Zhang C, Fan X, Xu X, Yang X, Wang X and Liang HP: Evodiamine induces caspase-dependent apoptosis and S phase arrest in human colon Lovo cells. Anticancer Drugs. 21:766–776. 2010.PubMed/NCBI View Article : Google Scholar
8	Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010.PubMed/NCBI View Article : Google Scholar
9	Lynch TJ, Adjei AA, Bunn PA Jr, Eisen TG, Engelman J, Goss GD, Haber DA, Heymach JV, Jänne PA, Johnson BE, et al: Summary statement: Novel agents in the treatment of lung cancer: Advances in epidermal growth factor receptor-targeted agents. Clin Cancer Res. 12 (14 Pt 2):4365s–4371s. 2006.PubMed/NCBI View Article : Google Scholar
10	Reya T, Morrison SJ, Clarke MF and Weissman IL: Stem cells, cancer, and cancer stem cells. Nature. 414:105–111. 2001.PubMed/NCBI View Article : Google Scholar
11	Wang JC and Dick JE: Cancer stem cells: Lessons from leukaemia. Trends Cell Biol. 15:494–501. 2005.PubMed/NCBI View Article : Google Scholar
12	Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CH, Jones DL, Visvader J, Weissman IL and Wahl GM: Cancer stem cells-perspectives on current status and future directions: AACR workshop on cancer stem cells. Cancer Res. 66:9339–9344. 2006.PubMed/NCBI View Article : Google Scholar
13	Tirino V, Camerlingo R, Franco R, Malanga D, La Rocca A, Viglietto G, Rocco G and Pirozzi G: The role of CD133 in the identification and characterisation of tumour-initiating cells in non-small-cell lung cancer. Eur J Cardiothorac Surg. 36:446–453. 2009.PubMed/NCBI View Article : Google Scholar
14	Chiou SH, Wang ML, Chou YT, Chen CJ, Hong CF, Hsieh WJ, Chang HT, Chen YS, Lin TW, Hsu HS and Wu CW: Coexpression of Oct4 and Nanog enhances malignancy in lung adenocarcinoma by inducing cancer stem cell-like properties and epithelial-mesenchymal transdifferentiation. Cancer Res. 70:10433–10444. 2010.PubMed/NCBI View Article : Google Scholar
15	Yuan P, Kadara H, Behrens C, Tang X, Woods D, Solis LM, Huang J, Spinola M, Dong W, Yin G, et al: Sex determining region Y-Box 2 (SOX2) is a potential cell-lineage gene highly expressed in the pathogenesis of squamous cell carcinomas of the lung. PLoS One. 5(e9112)2010.PubMed/NCBI View Article : Google Scholar
16	Eramo A, Lotti F, Sette G, Pilozzi E, Biffoni M, Di Virgilio A, Conticello C, Ruco L, Peschle C and De Maria R: Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ. 15:504–514. 2008.PubMed/NCBI View Article : Google Scholar
17	Justilien V, Regala RP, Tseng IC, Walsh MP, Batra J, Radisky ES, Murray NR and Fields AP: A. Fields, Matrix Metalloproteinase-10 is required for lung cancer stem cell maintenance, tumor initation and metastatic potential. PLoS One. 7(e35040)2010.PubMed/NCBI View Article : Google Scholar
18	Zhang L, Wang D, Li Y, Liu Y, Xie X, Wu Y, Zhou Y, Ren J, Zhang J, Zhu H and Su Z: CCL21/CCR7 axis contributed to CD133+ pancreatic cancer stem-like cell metastasis via EMT and Erk/NF-kB pathway. PLoS One. 11(e0158529)2016.PubMed/NCBI View Article : Google Scholar
19	Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, et al: The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 133:704–715. 2008.PubMed/NCBI View Article : Google Scholar
20	Morel AP, Lièvre M, Thomas C, Hinkal G, Ansieau S and Puisieux A: Generation of breast cancer stem cells through epithelial-mesenchymal transition. PLoS One. 3(e2888)2008.PubMed/NCBI View Article : Google Scholar
21	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001.PubMed/NCBI View Article : Google Scholar
22	Spaderna S, Schmalhofer O, Hlubek F, Berx G, Eger A, Merkel S, Jung A, Kirchner T and Brabletz T: A transient, EMT-linked loss of basement membranes indicates metastasis and poor survival in colorectal cancer. Gastroenterology. 131:830–840. 2006.PubMed/NCBI View Article : Google Scholar
23	Prall F: Tumour budding in colorectal carcinoma. Histopathology. 50:151–162. 2007.PubMed/NCBI View Article : Google Scholar
24	Tiwari N, Gheldof A, Tatari M and Christofori G: EMT as the ultimate survival mechanism of cancer cells. Semin Cancer Biol. 22:194–207. 2012.PubMed/NCBI View Article : Google Scholar